X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Lupin Ltd with Strides Arcolab - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

LUPIN LTD vs STRIDES SHASUN LTD - Comparison Results

LUPIN LTD    Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

STRIDES SHASUN LTD 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    LUPIN LTD STRIDES SHASUN LTD LUPIN LTD/
STRIDES SHASUN LTD
 
P/E (TTM) x 16.6 14.0 118.6% View Chart
P/BV x 3.9 1.9 204.2% View Chart
Dividend Yield % 0.8 0.5 144.8%  

Financials

 LUPIN LTD   STRIDES SHASUN LTD
EQUITY SHARE DATA
    LUPIN LTD
Mar-16
STRIDES SHASUN LTD
Mar-16
LUPIN LTD/
STRIDES SHASUN LTD
5-Yr Chart
Click to enlarge
High Rs2,1271,413 150.6%   
Low Rs1,294848 152.6%   
Sales per share (Unadj.) Rs304.1353.3 86.1%  
Earnings per share (Unadj.) Rs50.423.4 215.5%  
Cash flow per share (Unadj.) Rs60.741.0 148.0%  
Dividends per share (Unadj.) Rs7.505.00 150.0%  
Dividend yield (eoy) %0.40.4 99.1%  
Book value per share (Unadj.) Rs243.8320.4 76.1%  
Shares outstanding (eoy) m450.5889.35 504.3%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x5.63.2 175.8%   
Avg P/E ratio x33.948.3 70.2%  
P/CF ratio (eoy) x28.227.6 102.2%  
Price / Book Value ratio x7.03.5 198.9%  
Dividend payout %14.921.4 69.6%   
Avg Mkt Cap Rs m770,740100,988 763.2%   
No. of employees `00016.44.7 348.6%   
Total wages/salary Rs m21,0774,988 422.5%   
Avg. sales/employee Rs Th8,379.66,730.0 124.5%   
Avg. wages/employee Rs Th1,289.01,063.6 121.2%   
Avg. net profit/employee Rs Th1,388.7445.5 311.7%   
INCOME DATA
Net Sales Rs m137,01631,564 434.1%  
Other income Rs m1,8771,212 154.8%   
Total revenues Rs m138,89332,776 423.8%   
Gross profit Rs m37,5355,213 720.0%  
Depreciation Rs m4,6351,573 294.7%   
Interest Rs m4461,803 24.7%   
Profit before tax Rs m34,3303,049 1,125.9%   
Minority Interest Rs m-88127 -69.2%   
Prior Period Items Rs m0-27 0.0%   
Extraordinary Inc (Exp) Rs m0-371 0.0%   
Tax Rs m11,536689 1,675.4%   
Profit after tax Rs m22,7072,089 1,086.8%  
Gross profit margin %27.416.5 165.9%  
Effective tax rate %33.622.6 148.8%   
Net profit margin %16.66.6 250.3%  
BALANCE SHEET DATA
Current assets Rs m97,79035,949 272.0%   
Current liabilities Rs m53,87219,402 277.7%   
Net working cap to sales %32.152.4 61.1%  
Current ratio x1.81.9 98.0%  
Inventory Days Days8571 119.4%  
Debtors Days Days121127 95.6%  
Net fixed assets Rs m86,37934,478 250.5%   
Share capital Rs m901894 100.9%   
"Free" reserves Rs m105,73522,601 467.8%   
Net worth Rs m109,84428,632 383.6%   
Long term debt Rs m53,73927,455 195.7%   
Total assets Rs m224,37876,591 293.0%  
Interest coverage x77.92.7 2,896.2%   
Debt to equity ratio x0.51.0 51.0%  
Sales to assets ratio x0.60.4 148.2%   
Return on assets %10.35.1 203.0%  
Return on equity %20.77.3 283.3%  
Return on capital %21.28.2 259.6%  
Exports to sales %49.148.1 102.0%   
Imports to sales %7.414.5 51.5%   
Exports (fob) Rs m67,24415,192 442.6%   
Imports (cif) Rs m10,1994,565 223.4%   
Fx inflow Rs m71,40516,612 429.8%   
Fx outflow Rs m17,8075,292 336.5%   
Net fx Rs m53,59811,320 473.5%   
CASH FLOW
From Operations Rs m-3,690717 -514.9%  
From Investments Rs m-69,434-22,284 311.6%  
From Financial Activity Rs m58,12629,488 197.1%  
Net Cashflow Rs m-14,9988,073 -185.8%  

Share Holding

Indian Promoters % 46.6 27.7 168.2%  
Foreign collaborators % 0.2 0.0 -  
Indian inst/Mut Fund % 11.3 37.8 29.9%  
FIIs % 31.9 8.6 370.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.1 25.9 39.0%  
Shareholders   98,259 56,241 174.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare LUPIN LTD With:   ORCHID PHARMA LTD  CIPLA  ABBOTT INDIA  ALEMBIC LTD  WYETH LTD  

Compare LUPIN LTD With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Flat Note; Dr Reddy's & Lupin Surge over 2%(Closing)

Indian share markets continued to trade just above the dotted line in the afternoon session in a lackluster day of trading. At the closing bell, the BSE Sensex closed higher by 33 points.

Related Views on News

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Lupin: Decline in US Business Impacts Overall Growth (Quarterly Results Update - Detailed)

May 29, 2017

Currency fluctuation and one time provision impacts operating margins.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

More Views on News

Most Popular

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

Aug 10, 2017

Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

LUPIN LTD SHARE PRICE


Aug 22, 2017 (Close)

TRACK LUPIN LTD

  • Track your investment in LUPIN LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

LUPIN LTD 8-QTR ANALYSIS

COMPARE LUPIN LTD WITH

MARKET STATS